Table 3: Comparison between some clinical manifestation in patients with class IV segmental (S) versus global (G) proliferative lupus nephritis (LN) at the time of renal biopsy.

Clinical manifestationClass IV-S LN ( 𝑛 = 4 1 )Class IV-G LN ( 𝑛 = 2 2 )
number (%) of cases

Mucocutaneous manifestations 28 (68,29%)12 (54,54%)
40 (63,49%) patients

Pyrexia11 (39,02%)19 (68,18%)
30 (51,72%) patients

Musculoskeletal manifestations16 (26,83%)15 (86,36%)
31 (49,21%) patients

Gastrointestinal symptoms (lupus hepatitis or pancreatitis)2 (4,88%)1 (4,54%)
3 (4,48%) patients

Ascites2 (4,88%)3 (13,64%)
5 (7,94%) patients

Pneumonitis2 (4,88%)2 (9,09%)
4 (6,35%) patients

Pleural effusion with dyspnoea4 (9,76%)7 (31,82%)
11 (17,46%) patients

Cardiovascular symptoms (endocarditis/myocarditis/aortitis) 5 (12,195%)4 (18,18%)
9 (14,28%) patients

Pericarditis4 (9,76%)10 (45,45%)
14 (22,22%) patients

Psychosis1 (2,44%)3 (13,64%)
4 (6,35%) patients

Epilepsy2 (4,88%)2 (9,09%)
4 (6,35%) patients

Primary ocular manifestations (retinal vasculitis/optic neuritis)6 (14,63%)10 (45,45%)
16 (25,4%) patients

Anemia24 (58,53%)16 (72,73%)
40 (63,49%) patients

Thrombocytopenia25 (60,98%)19 (86,36%)
44 (69,84%) patients

Leukopenia12 (29,29%)11 (50%)
23 (36,51%) patients

Lymphopenia22 (53,68%)16 (72,73%)
38 (60,32%) patients

Nephrotic syndrome13 (31,71%)16 (72,73%)
26 (41,27%) patients